Finally Food and Drug Administration(FDA) has given the permission to Allergen Inc. to sale its eye implant Ozurdex to treat macular edema.
The macula of the eye is the yellow central area of the retina. When fluid and protein deposits collect on or under the macula of the eye, it is called Macular edema.
Retinal blood vessel obstruction, eye inflammation, and age-related macular degeneration have all been associated with macular edema. The macula may also be affected by swelling following cataract extraction, though typically this resolves itself naturally.
Macular edema rarely causes a permanent loss of vision, but the recovery is often a slow, gradual process. The majority of patients recover in 2 to 15 months.
According to Allergan Ozurdex is the first product approved to treat macular edema following blockage of retinal veins. Ozurdex is a biodegradable implant that is injected into the eye, where it releases a cortical steroid called dexamethasone, treating macular edema and improving vision.
FDA approved the product to treat macular edema caused by occlusion, or blockage, of the branch and central retinal veins. Retinal vein occlusion is the second most common disease of the retinal veins, after diabetic retinopathy.
Allergan, is a eye health care company, which is focused on developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to see more clearly, move more freely and express themselves more fully.
For further details of Ozurdex you may contact Allergan, Inc. at,
2525 Dupont Drive
Irvine, CA 92612
Phone: (714) 246-4500
Fax: (714) 246-4971
Web Site: www.allergan.com